Pulmonx Corp generated revenue of $22.8 million for the three months ended September 30, 2026, up 6.2%, while gross margin rose to 76.2% and net loss narrowed 39.9% to $8.4 million.
LUNG · Pulmonx Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Worldwide revenue for the third quarter of 2026 was $22.8 million, a 6% increase from the prior year, and management called this a first return to global year-over-year growth. U.S. revenue rose 7% to $14.9 million, and full-year 2026 revenue guidance of $90 to $92 million was reiterated. Adjusted EBITDA loss fell nearly 60% to $3.5 million.
Pulmonx reported third-quarter 2026 revenue of $22.8 million, a 6% increase over the same period last year, and returned to year-over-year growth. Net loss narrowed to $8.4 million, or $0.19 per share, from $14.0 million, or $0.34 per share, a year earlier. For full-year 2026, revenue is still expected to be in the range of $90 million to $92 million, with gross margin now expected at approximately 77%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 27, 2026TL;DR. Pulmonx returned to Q3 revenue growth, improved gross margin and operating leverage, reiterated $90 million–$92 million revenue guidance, and expects approximately $22 million of 2026 cash burn, 30% below 2025. AeroSeal enrollment remains on track and China commercial activity has restarted, while nine-month revenue and losses remain headwinds and material AeroSeal European revenue is not expected until 2028.
- + Worldwide revenue returned to year-over-year growth in Q3 2026. new
- + Gross margin improved and operating leverage reduced Q3 losses. new
- + Management updated full-year gross-margin and operating-expense expectations while reiterating revenue guidance. new
- + Cash burn is expected to decline substantially, and management sees a pathway to cash-flow break-even. new
- + AeroSeal enrollment remains on track, and management believes it can expand the addressable market by roughly 20% globally. new
- − Nine-month worldwide revenue remained down 2.5% year over year. new
- − International revenue growth was constrained by the absence of sales to the China distributor during the quarter. new
- − Management did not provide 2027 guidance or a timeframe for sustaining double-digit growth. new
- − AeroSeal's European launch is expected to be limited in 2027, with material revenue anticipated in 2028. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $5.1M | the second quarter of 2026 | — |
| Constant currency revenue change | -6% | the second quarter of 2026 | — |
| Gross margin | 78% | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUNG
this stock
Pulmonx Corp
|
$119.33M | +24.0% | +8.0% | — | 1.8% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 15
Pulmonx Corp generated revenue of $22.8 million for the three months ended September 30, 2026, up 6.2%, while gross margin rose to 76.2% and net loss narrowed 39.9% to $8.4 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUNG | -8.7% | +45.7% | +72.3% | -8.8% | +24.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -3.2% | +52.0% | +78.0% | -3.6% | +19.0% |